Microphthalmia-Associated Transcription Factor: A Differentiation Marker in Uveal Melanoma

  • Maria Chiara Gelmi
  • , Robert M. Verdijk
  • , Laurien E. Houtzagers
  • , Pieter A. van der Velden
  • , Wilma G.M. Kroes
  • , Gregorius P.M. Luyten
  • , T. H.Khanh Vu
  • , Martine J. Jager*
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
61 Downloads (Pure)

Abstract

Microphthalmia-associated transcription factor (MITF) is an important regulator of melanogenesis and melanocyte development. In cutaneous melanoma, MITF loss has been linked to an increased expression of stem cell markers, a shift in epithelial-to-mesenchymal transition (EMT)-related factors, and increased inflammation. We explored the role of MITF in Uveal Melanoma (UM) using a cohort of 64 patients enucleated at the Leiden University Medical Center. We analysed the relation between MITF expression and clinical, histopathological and genetic features of UM, as well as survival. We performed differential gene expression and gene set enrichment analysis using mRNA microarray data, comparing MITF-low with MITF-high UM. MITF expression was lower in heavily pigmented UM than in lightly pigmented UM (p = 0.003), which we confirmed by immunohistochemistry. Furthermore, MITF was significantly lower in UM with monosomy 3/BAP1 loss than in those with disomy 3/no BAP1 loss (p < 0.001) and with 8q gain/amplification 8q (p = 0.02). Spearman correlation analysis showed that a low MITF expression was associated with an increase in inflammatory markers, hallmark pathways involved in inflammation, and epithelial-mesenchymal transition. Similar to the situation in cutaneous melanoma, we propose that MITF loss in UM is related to de-differentiation to a less favourable EMT profile and inflammation.

Original languageEnglish
Article number8861
JournalInternational Journal of Molecular Sciences
Volume24
Issue number10
DOIs
Publication statusPublished - 16 May 2023

Bibliographical note

Funding Information:
M.C. Gelmi was funded by the Bontius Foundation, Oogfonds, the Sam Fund, the LUF, P.A. Jager-van Gelder Fund, the Blinden-Penning foundation, and ASROO (Associazione Scientifica Retinoblastoma ed Oncologia Oculare). The sponsor or funding organization had no role in the design or conduct of this research.

Publisher Copyright:
© 2023 by the authors.

Fingerprint

Dive into the research topics of 'Microphthalmia-Associated Transcription Factor: A Differentiation Marker in Uveal Melanoma'. Together they form a unique fingerprint.

Cite this